Is There a Pill Form of Tirzepatide? What UK Patients Need to Know

The misconception: 'Eli Lilly must make a tirzepatide pill by now'

It is easy to assume that because oral versions of similar medicines exist, a tirzepatide tablet must be quietly available somewhere. The assumption is understandable but currently incorrect. Eli Lilly has investigated oral tirzepatide in early-stage research, but no oral formulation has cleared phase 3 trials, received regulatory approval or been licensed for use in any country. Tirzepatide reaches the bloodstream reliably only when injected under the skin; getting a large peptide molecule through the stomach wall in useful quantities is a genuine biochemical challenge, and the science is not yet there for commercial use.

This matters because some sellers online describe tirzepatide capsules or tablets as if they were real products. They are not. If you have been wondering whether there is a Mounjaro pill, the answer is that any listing claiming to offer an oral form of tirzepatide is either mislabelled or counterfeit, a serious safety concern the MHRA has flagged repeatedly in its guidance on reporting suspect weight-loss products.

The honest answer to this page's question is therefore simple: if you want tirzepatide, the pen is the only option. If you specifically want to avoid injections, there is now a licensed oral alternative worth knowing about.

What has actually arrived: the UK's first oral GLP-1 weight-loss medicine

The pill form of GLP-1 treatment that has reached the UK is oral semaglutide, branded as Wegovy tablets. The MHRA approved it on 11 June 2026, making the UK the first country in Europe to licence an oral GLP-1 for weight management. It works along a single GLP-1 pathway (rather than the dual GIP and GLP-1 pathway that Mounjaro uses), and it comes as a once-daily tablet rather than a weekly injection.

In the OASIS 4 trial, participants lost an average of around 13.6% of their body weight over 64 weeks. Among those who stayed fully adherent to the regimen, the average was closer to 17%. Those figures sit below the headline results for tirzepatide at its higher doses (SURMOUNT-1 showed roughly 20–21% average weight reduction at 15 mg over 72 weeks, as published in the New England Journal of Medicine) but for many people, not having to inject is the deciding factor.

The tablet has one practical requirement: it must be taken first thing in the morning, on an empty stomach, with a small amount of plain water, then nothing else for at least 30 minutes. Room-temperature storage makes it genuinely travel-friendly. Our guide to tirzepatide in pill form sets out the full comparison between the injection and oral options in more detail, and our dedicated page on Mounjaro in pill form explores what that would mean in practice for patients considering their options.

So which is right for you: the Mounjaro pen or an oral option?

That is precisely the kind of question a prescriber needs to weigh up. The two medicines work differently, titrate differently and carry somewhat different side-effect profiles, though both share the GI-led effects (nausea, loose stools, reduced appetite) that are typical of GLP-1 treatment, as the NHS tirzepatide page describes. Mounjaro's dual-receptor mechanism is currently unique among UK-licensed weight medicines, and clinical trial data suggest greater average weight loss than semaglutide at comparable durations. Whether that difference matters for a specific patient depends on their comorbidities, their starting weight, and how they respond.

Some patients arrive having already tried a GLP-1 injection and want to explore alternatives. Others have a strong preference against needles from the start. Others are thinking about cost, and if that is a live consideration, our Mounjaro pricing context page explains how the UK private market has shifted since Eli Lilly revised its list prices in September 2025.

Worth knowing: Mounjaro is a Prescription-Only Medicine. What arrives, once a prescriber approves treatment, is a KwikPen, a pre-filled device about the length of a marker pen, containing four weekly doses. For anyone nervous about injections, it is smaller and simpler than most people expect.

What nume offers, and how a clinical review works here

At nume, every consultation is read by a GPhC-registered Independent Prescriber, a real clinician, same day. There are no algorithms making approval decisions. The process covers your medical history, current medicines, BMI, and goals; identity and weight are verified before any prescription is issued. If you are exploring whether the Mounjaro pen or an oral weight-loss medicine is the right fit, our prescribers work through exactly that question with you. You can browse common questions ahead of your consultation, or go straight to our treatment page to speak to our prescribers.